维得利珠单抗治疗对炎症性肠病患者肠外表现的影响:一项嵌套于OBSERV-IBD队列的多中心队列研究
该多中心队列研究纳入173例克罗恩病和121例溃疡性结肠炎患者,评估维得利珠单抗对肠外表现(EIM)的疗效。基线时49例(16.7%)有EIM,第54周时炎症性关节痛/关节炎完全缓解21例(44.7%),皮肤EIM完全缓解3例(75%)。EIM完全缓解与IBD临床缓解及EIM近期发作相关。
要点
- 维得利珠单抗治疗常伴随EIM改善,与IBD静止期及EIM近期发作相关。
- 第54周炎症性关节痛/关节炎完全缓解率为44.7%(21例)。
- 治疗中可能出现矛盾性皮肤表现和炎症性关节痛/关节炎。
核心结论
- 维得利珠单抗治疗常伴随EIM改善,这与IBD静止期及EIM近期发作相关;但治疗中可能出现矛盾性皮肤表现和炎症性关节痛/关节炎。
研究设计与样本
- 多中心队列研究,嵌套于OBSERV-IBD队列;2014年6月至12月期间,173例克罗恩病和121例溃疡性结肠炎患者接受维得利珠单抗治疗,随访至第54周。
主要发现
- 基线时49例(16.7%)患者有EIM,其中47例为炎症性关节痛/关节炎,4例为皮肤病变,2例同时有风湿性和皮肤EIM。
- 第54周时,炎症性关节痛/关节炎完全缓解21例(44.7%),皮肤EIM完全缓解3例(75%)。
- 多因素分析显示,炎症性关节痛/关节炎完全缓解与IBD临床缓解相关(OR=1.89,95%CI 1.05-3.41,P=0.03),与炎症性关节痛/关节炎近期发作相关(OR=1.99,95%CI 1.12-3.52,P=0.02)。
- 随访期间,基线无EIM的患者中34例(13.8%)新发炎症性关节痛/关节炎,大多为外周关节痛无关节炎证据;14例(4.8%)新发矛盾性皮肤表现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut-specificity. AIM: To assess effectiveness of vedolizumab for EIM in patients with inflammatory bowel disease (IBD) in a large real-life experience cohort. METHODS: Between June and December 2014, 173 patients with Crohn's disease and 121 with ulcerative colitis were treated with vedolizumab. Patients were followed until week 54. EIM activity was assessed at weeks 0, 6, 14, 22, 30 and 54 by using a 3-step scale: complete remission, partial response and no response. RESULTS: At baseline, 49 (16.7%) patients had EIMs of which 47 had inflammatory arthralgia/arthritis, four had cutaneous lesions and two had both rheumatologic and skin EIM. At week 54, 21 (44.7%) patients had complete remission for inflammatory arthralgia/arthritis and three (75%) for cutaneous EIM. In multivariate analysis, complete remission of inflammatory arthralgia/arthritis was associated with clinical remission of IBD (OR = 1.89, IC95% [1.05-3.41], P = .03) and recent onset of inflammatory arthralgia/arthritis (OR = 1.99, IC95% [1.12-3.52], P = .02). During the follow-up period, 34 (13.8%) patients without any EIM at baseline, developed incident cases of inflammatory arthralgia/arthritis consisting mostly of peripheral arthralgia without evidence of arthritis and 14 (4.8%) incident cases of paradoxical skin manifestation. CONCLUSION: Vedolizumab therapy is commonly associated with improvement in EIM. This was associated with quiescent IBD and recent EIM. However, paradoxical skin manifestation and inflammatory arthralgia/arthritis may occur upon vedolizumab therapy.
引用
- Tadbiri S, Peyrin-Biroulet L, Serrero M, et al. Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther. 2017. PMID: 29250803. doi:10.1111/apt.14419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。